Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations

Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations

Abstract Background This cost of illness study aimed to determine economic burden of short-acting β2-agonist (SABA) overuse in Türkiye from payer perspective with respect to the updated GINA 2022 treatment recommendations. Methods A total of 3,034,879 asthma patients comprised the study population,...

Full description

Bibliographic Details
Main Authors: Arzu Yorgancıoğlu, Kurtuluş Aksu, Ceyhun Cura, Yiğit Yaman, Melda Dinç, Simten Malhan, the SABINA Türkiye Study Group*
Format: Article
Language:English
Published: BMC 2024-10-01
Series:BMC Pulmonary Medicine
Subjects:
Adult asthma
Asthma severity
GINA updates
SABA overuse
Cost analysis
Cost burden
Online Access:https://doi.org/10.1186/s12890-024-03327-9

Internet

https://doi.org/10.1186/s12890-024-03327-9

Similar Items